Northfield Labs Reports Verified Data From Troubled Phase III PolyHeme Study
This article was originally published in Pharmaceutical Approvals Monthly
Northfield Laboratories is moving ahead with plans to file a BLA for its investigational red blood cell substitute PolyHeme, despite protocol violations that triggered a data verification process and a planned safety analysis to gain insight on myocardial infarction data
You may also be interested in...
FDA sends "refuse-to-file" letter to Northfield Labs in November regarding the firm's PolyHeme BLA submission. Northfield submitted a BLA for the polymerized blood substitute Aug. 28. According to the firm, the agency is "seeking additional information before accepting the application for filing." Northfield will be discussing the necessary steps with FDA "over the next few months"
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.